Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $35.6 million.

  • Foghorn Therapeutics' Cash from Investing Activities rose 15801.68% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 91768.4%. This contributed to the annual value of -$29.9 million for FY2024, which is 12070.2% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash from Investing Activities stood at $35.6 million for Q3 2025, which was up 15801.68% from $33.8 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Cash from Investing Activities registered a high of $77.1 million during Q2 2021, and its lowest value of -$159.4 million during Q1 2022.
  • Over the past 5 years, Foghorn Therapeutics' median Cash from Investing Activities value was $27.1 million (recorded in 2024), while the average stood at $273947.4.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 352922.6% in 2021, then crashed by 478834.71% in 2022.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Cash from Investing Activities stood at $9.7 million in 2021, then tumbled by 167.27% to -$6.5 million in 2022, then surged by 674.54% to $37.4 million in 2023, then crashed by 40.37% to $22.3 million in 2024, then soared by 59.58% to $35.6 million in 2025.
  • Its Cash from Investing Activities was $35.6 million in Q3 2025, compared to $33.8 million in Q2 2025 and $29.4 million in Q1 2025.